Loading...
Please wait, while we are loading the content...
Advances in the Inhibitors of Janus Kinase
| Content Provider | Semantic Scholar |
|---|---|
| Author | Jiang, Jun-Jie Wang, Xiaoying Zhang, Yan Jin, Yi Lin, Jun |
| Copyright Year | 2014 |
| Abstract | In recent years, for the lesion site, studies at the molecular level of drugs targeting protein molecules has been a major research method for exploiting new, high-efficiency drugs with low toxicity [1]. Janus kinases (JAKs) are important signal transducers of many cytokines, growth factors and interferon. In recent years, it has been found in cancer cells and cells transfected with oncogenes that there would be a significant enhancement in the expression of JAKs. Also, the expression of JAKs has a close relationship with inflammation and autoimmune diseases and immune rejection of the allograft following formation [2]. With the research development of JAKs, a large number of safe, high-efficiency and highly selective JAKs inhibitors have been designed, which can selectively block JAKs signal transduction systems. According to clinical trial results, JAKs have high selectivity, high bioavailability, therapeutic activity and are well tolerated, which makes the treatment of diseases using JAKs possible [3]. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.omicsonline.org/open-access/advances-in-the-inhibitors-of-janus-kinase-2161-0444.1000540.pdf |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Autoimmune Diseases Drug Delivery Systems Janus kinase Janus kinase 2 Neoplasms Oncogenes Rejection sampling Second Generation Multiplex Plus Selectivity (electronic) Side effect (computer science) Signal Transduction Transducer Transducers Transduction (machine learning) cellular targeting |
| Content Type | Text |
| Resource Type | Article |
